What is Jazz Pharmaceuticals's market cap?

Jazz Pharmaceuticals (JAZZ) has a market capitalization of $16.0B and trades on NASDAQ.

What is Jazz Pharmaceuticals's revenue and profitability?

Jazz Pharmaceuticals generated $4.4B in trailing twelve-month revenue with a net loss of $266.5M, representing a net margin of -8.9%, with free cash flow of $1.3B. These figures are based on the Q1 2026 filing.

Who are Jazz Pharmaceuticals's competitors?

Jazz Pharmaceuticals's key competitors include Harmony Biosciences, Amneal Pharmaceuticals, Alkermes, and others. These companies compete in similar markets and product categories.

Who does Jazz Pharmaceuticals partner with?

Jazz Pharmaceuticals's notable partners include Zymeworks, PharmaMar, Hikma Pharmaceuticals, and others.

What subsidiaries does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals's subsidiaries include GW Pharmaceuticals, Chimerix.

Where is Jazz Pharmaceuticals headquartered?

Jazz Pharmaceuticals is headquartered in Ireland and employs approximately 2,800 people. It has been publicly traded since 2007.

Jazz Pharmaceuticals

JAZZ

Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing life-changing medicines for rare diseases with limited therapeutic options.

Market cap

$16.05B+128%

Revenue$4.4B+9.2%

Net income-$266.5M-148%

Free cash flow$1.3B-16.1%

EPS (diluted)-$4.75-155%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$1.1BBeat by $90.2M EPS$6.34Beat by $1.67

Read the full report

Next report

Aug 3, 2026 (In 5 days)

Revenue estimate$1.1B

EPS estimate$6.18

Financials

Q1 2026

Income statement

See full

Revenue$1.1B+19.1%

Operating income$336.6M+702%

Net income$293.1M+417%

EPS (diluted)$4.43+391%

Balance sheet

See full

Cash & equivalents$667.5M-64.1%

Total debt$5.4B-0.1%

Total equity$4.5B+8.6%

Total assets$11.9B+2.8%

Cash flow

See full

Operating cash flow$408.2M-5.0%

CapEx$19.7M+41.7%

Free cash flow$388.5M-6.6%

Valuation & ratios

Valuation

See full

Market cap$16.05B+128%

Enterprise value$20.78B+83.4%

P/S3.6×+1.9×

Profitability

See full

FCF margin28.6%-8.6pp

Returns & leverage

See full

Debt / equity1.2×-0.1×

Current ratio2×-1.3×

Segments

By product

See full

Xywav$408.2M+18.4%

Epidiolex/Epidyolex$249.8M+14.7%

Rylaze/Enrylaze$103.7M+10.1%

Zepzelca$101.0M+60.3%

Defitelio/defibrotide$47.4M+16.5%

By geography

See full

Europe$92.4M+10.5%

All other$16.7M+2.5%

Competitors

By market cap

Amgen$203.07B+25.3%

Jazz Pharmaceuticals$16.0B+126%

Alkermes$8.8B+104%

Xenon Pharmaceuticals$6.4B+168%

Amneal Pharmaceuticals, Inc.$5.8B+126%

Harmony Biosciences Holdings, Inc.$2.1B+1.5%

Polaryx Therapeutics, Inc. $97.7M—

Jupiter Neurosciences, Inc.$5.5M-89.5%

By revenue growth

Harmony Biosciences Holdings, Inc.+20.7%

Alkermes+10.8%

Jazz Pharmaceuticals+9.2%

Amgen+9.1%

Amneal Pharmaceuticals, Inc.+7.6%

Xenon Pharmaceuticals-100%

By net margin

Amgen20.96%+3.6pp

Harmony Biosciences Holdings, Inc.16.2%-4.3pp

Amneal Pharmaceuticals, Inc.4.01%+4.5pp

Alkermes3.97%-19.2pp

Jazz Pharmaceuticals-8.86%-19.8pp

Xenon Pharmaceuticals-4,612.13%—

Profile

Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing life-changing medicines for rare diseases with limited therapeutic options. The company maintains a leading position in sleep medicine and has significantly expanded its portfolio into high-growth areas including oncology and rare epilepsies. Its value proposition centers on identifying highly differentiated therapies for small patient populations and supporting them through an efficient, specialized commercial model.

Competitive position

Jazz is a leader in the oxybate market for sleep disorders and a pioneer in cannabinoid-based epilepsy treatments, maintaining a robust pipeline through strategic acquisitions and licensing.

GeographiesUnited States, Europe, Canada, Australia

Customer segmentsSpecialty pharmacies, Hospitals, Wholesale distributors

Business modelResearch and Development, Direct-to-specialist commercialization, Licensing and royalties

SuppliersContract Manufacturing Organizations (CMOs), Active Pharmaceutical Ingredient (API) suppliers, Cannabis cultivation facilities, Clinical research organizations

CustomersSpecialty pharmacies, Full-line wholesalers, Hospitals, Government healthcare programs

CountryIreland

Listed2007

Employees2.8K

CEORenee D. Gala

SectorHealthcare

IndustryBiotechnology

Websitejazzpharmaceuticals.com

FilingsSEC EDGAR

Ask your AI about Jazz Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Jazz Pharmaceuticals's market cap?: Jazz Pharmaceuticals (JAZZ) has a market capitalization of $16.0B and trades on NASDAQ.
What is Jazz Pharmaceuticals's revenue and profitability?: Jazz Pharmaceuticals generated $4.4B in trailing twelve-month revenue with a net loss of $266.5M, representing a net margin of -8.9%, with free cash flow of $1.3B. These figures are based on the Q1 2026 filing.
Who are Jazz Pharmaceuticals's competitors?: Jazz Pharmaceuticals's key competitors include Harmony Biosciences, Amneal Pharmaceuticals, Alkermes, and others. These companies compete in similar markets and product categories.
Who does Jazz Pharmaceuticals partner with?: Jazz Pharmaceuticals's notable partners include Zymeworks, PharmaMar, Hikma Pharmaceuticals, and others.
What subsidiaries does Jazz Pharmaceuticals have?: Jazz Pharmaceuticals's subsidiaries include GW Pharmaceuticals, Chimerix.
Where is Jazz Pharmaceuticals headquartered?: Jazz Pharmaceuticals is headquartered in Ireland and employs approximately 2,800 people. It has been publicly traded since 2007.